Breaking News Instant updates and real-time market news.

CGC

Canopy Growth

$52.47 /

+2.71 (+5.45%)

, STZ

Constellation Brands

$216.31 /

-0.69 (-0.32%)

08:32
09/25/18
09/25
08:32
09/25/18
08:32

Canopy Growth initiated with a Buy at Benchmark

Benchmark analyst Mike Hickey initiated Canopy Growth (CGC) with a Buy rating and C$100 price target, citing Canopy's early leadership in the medical cannabis market and upcoming legalization of recreational cannabis in Canada and the meaningful investment from Constellation Brands (STZ). That investment accelerates the ongoing build-out of its international production and distribution operations and domestic retail infrastructure to meet rapidly growing global demand, Hickey tells investors.

CGC

Canopy Growth

$52.47 /

+2.71 (+5.45%)

STZ

Constellation Brands

$216.31 /

-0.69 (-0.32%)

STZ.B

Constellation Brands; also tag STZ

$220.00 /

+ (+0.00%)

  • 04

    Oct

  • 04

    Oct

  • 13

    Oct

  • 28

    Oct

CGC Canopy Growth
$52.47 /

+2.71 (+5.45%)

09/20/18 Stifel
Top 22 Canadian cannabis stocks up 127% since Constellation pact, says Stifel
09/19/18
Canopy Growth price target raised to C$95 from C$51 at Garnier
09/10/18
Fly Intel: Today's top analyst calls on Wall Street
09/04/18 Cowen
Canopy Growth price target raised to C$74 from C$56 at Cowen
STZ Constellation Brands
$216.31 /

-0.69 (-0.32%)

09/14/18 Guggenheim
Constellation Brands initiated with a Sell, growth decelerating, says Guggenheim
09/13/18 Guggenheim
Constellation Brands initiated with a Sell at Guggenheim
STZ.B Constellation Brands; also tag STZ
$220.00 /

+ (+0.00%)

08/30/18 Stifel
Canopy Growth presentation thorough, but didn't include 'new news,' says Stifel

TODAY'S FREE FLY STORIES

Conference/Events
Brookfield Infrastructure Partners to host investor day » 17:46
09/19/21
09/19
17:46
09/19/21
17:46
BIP

Brookfield Infrastructure Partners

$55.30 /

-0.865 (-1.54%)

Investor Day to be held…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BIP Brookfield Infrastructure Partners
$55.30 /

-0.865 (-1.54%)

BIP Brookfield Infrastructure Partners
$55.30 /

-0.865 (-1.54%)

09/17/21 TD Securities
Brookfield Infrastructure Partners resumed with a Buy at TD Securities
09/09/21 BMO Capital
Brookfield Infrastructure Partners resumed with an Outperform at BMO Capital
08/31/21 Citi
Brookfield Infrastructure Partners price target raised to $57 from $54 at Citi
06/22/21 CIBC
Brookfield Infrastructure Partners resumed with an Outperformer at CIBC
BIP Brookfield Infrastructure Partners
$55.30 /

-0.865 (-1.54%)

BIP Brookfield Infrastructure Partners
$55.30 /

-0.865 (-1.54%)

Conference/Events
Brookfield Renewable to host investor day » 17:43
09/19/21
09/19
17:43
09/19/21
17:43
BEPC

Brookfield Renewable

$41.74 /

-0.03 (-0.07%)

Investor Day to be held…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BEPC Brookfield Renewable
$41.74 /

-0.03 (-0.07%)

07/21/21 JPMorgan
Brookfield Renewable price target raised to $52 from $49 at JPMorgan
06/28/21 Credit Suisse
Brookfield Renewable Partners upgraded to Outperform at Credit Suisse
04/26/21 Wells Fargo
Brookfield Renewable upgraded to Overweight from Equal Weight at Wells Fargo
03/31/21 JPMorgan
Brookfield Renewable initiated with a Neutral at JPMorgan
  • 11
    Feb
BEPC Brookfield Renewable
$41.74 /

-0.03 (-0.07%)

Conference/Events
Brookfield Business Partners to hold investor day » 17:40
09/19/21
09/19
17:40
09/19/21
17:40
BBU

Brookfield Business Partners

$42.21 /

+0.29 (+0.69%)

Investor Day to be held…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BBU Brookfield Business Partners
$42.21 /

+0.29 (+0.69%)

BBU Brookfield Business Partners
$42.21 /

+0.29 (+0.69%)

06/29/21 National Bank
Brookfield Business Partners price target raised to $60 from $56 at National Bank
06/11/21 Credit Suisse
Brookfield Business upgraded to Outperform from Neutral at Credit Suisse
05/21/21 Industrial Alliance
Brookfield Business Partners initiated with a Buy at Industrial Alliance
05/10/21 Credit Suisse
Brookfield Business downgraded to Neutral on valuation at Credit Suisse
BBU Brookfield Business Partners
$42.21 /

+0.29 (+0.69%)

BBU Brookfield Business Partners
$42.21 /

+0.29 (+0.69%)

Conference/Events
Salesforce to hold virtual investor day » 17:32
09/19/21
09/19
17:32
09/19/21
17:32
CRM

Salesforce

$260.52 /

+0.13 (+0.05%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CRM Salesforce
$260.52 /

+0.13 (+0.05%)

CRM Salesforce
$260.52 /

+0.13 (+0.05%)

09/17/21 Barclays
Salesforce price target raised to $330 from $320 at Barclays
08/27/21 Loop Capital
Salesforce price target raised to $265 from $235 at Loop Capital
08/27/21 Societe Generale
Salesforce price target raised to $321 from $290 at Societe Generale
08/26/21 RBC Capital
Salesforce assumed with an Outperform at RBC Capital
CRM Salesforce
$260.52 /

+0.13 (+0.05%)

CRM Salesforce
$260.52 /

+0.13 (+0.05%)

CRM Salesforce
$260.52 /

+0.13 (+0.05%)

CRM Salesforce
$260.52 /

+0.13 (+0.05%)

Conference/Events
CenterPoint Energy to hold virtual investor day » 17:30
09/19/21
09/19
17:30
09/19/21
17:30
CNP

CenterPoint Energy

$24.43 /

-0.215 (-0.87%)

Virtual Analyst Day to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CNP CenterPoint Energy
$24.43 /

-0.215 (-0.87%)

CNP CenterPoint Energy
$24.43 /

-0.215 (-0.87%)

06/14/21 Citi
CenterPoint Energy resumed with a Neutral at Citi
05/25/21 Barclays
CenterPoint Energy price target raised to $28 from $25 at Barclays
05/24/21 BofA
CenterPoint Energy upgraded to Buy from Neutral at BofA
05/13/21 Mizuho
CenterPoint Energy price target raised to $27 from $25.50 at Mizuho
CNP CenterPoint Energy
$24.43 /

-0.215 (-0.87%)

CNP CenterPoint Energy
$24.43 /

-0.215 (-0.87%)

Conference/Events
The Hanover to hold virtual investor day » 17:27
09/19/21
09/19
17:27
09/19/21
17:27
THG

The Hanover

$130.75 /

-0.8 (-0.61%)

Virtual Investor Day to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
THG The Hanover
$130.75 /

-0.8 (-0.61%)

THG The Hanover
$130.75 /

-0.8 (-0.61%)

08/16/21 Wolfe Research
The Hanover initiated with a Peer Perform at Wolfe Research
05/21/21 BofA
The Hanover initiated with a Buy at BofA
05/21/21 BofA
The Hanover initiated with a Buy at BofA
04/16/21 JMP Securities
Hanover Insurance price target raised to $145 from $140 at JMP Securities
THG The Hanover
$130.75 /

-0.8 (-0.61%)

Conference/Events
Kulicke & Soffa to hold virtual analyst and investor day » 17:24
09/19/21
09/19
17:24
09/19/21
17:24
KLIC

Kulicke & Soffa

$67.54 /

-0.68 (-1.00%)

Virtual Investor &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KLIC Kulicke & Soffa
$67.54 /

-0.68 (-1.00%)

KLIC Kulicke & Soffa
$67.54 /

-0.68 (-1.00%)

09/17/21 B. Riley
Kulicke & Soffa price target raised to $85 from $80 at B. Riley
08/06/21 Craig-Hallum
Kulicke & Soffa price target raised to $88 from $64 at Craig-Hallum
04/20/21 Craig-Hallum
Kulicke & Soffa price target raised to $83 from $61 at Craig-Hallum
04/20/21 B. Riley
Kulicke & Soffa price target raised to $75 from $69 at B. Riley
KLIC Kulicke & Soffa
$67.54 /

-0.68 (-1.00%)

Conference/Events
Academy Sports management to meet with UBS » 17:20
09/19/21
09/19
17:20
09/19/21
17:20
ASO

Academy Sports

$44.12 /

-1.945 (-4.22%)

Meeting to be held in New…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASO Academy Sports
$44.12 /

-1.945 (-4.22%)

ASO Academy Sports
$44.12 /

-1.945 (-4.22%)

09/13/21
Academy Sports files to sell 18.7M shares for KKR
09/10/21 Loop Capital
Academy Sports price target raised to $58 from $45 at Loop Capital
09/10/21 UBS
Academy Sports price target raised to $52 from $48 at UBS
08/11/21 Wells Fargo
Academy Sports transferred with an Overweight at Wells Fargo
ASO Academy Sports
$44.12 /

-1.945 (-4.22%)

  • 15
    Sep
  • 06
    May
  • 08
    Apr
  • 28
    Jan
  • 02
    Oct
ASO Academy Sports
$44.12 /

-1.945 (-4.22%)

ASO Academy Sports
$44.12 /

-1.945 (-4.22%)

ASO Academy Sports
$44.12 /

-1.945 (-4.22%)

Conference/Events
Morgan Stanley Asian gaming analyst to hold analyst/industry conference call » 17:17
09/19/21
09/19
17:17
09/19/21
17:17

Asiam Gaming &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

On The Fly
Box Office Battle: 'Shang-Chi' stays number 1 with $21.7M » 16:13
09/19/21
09/19
16:13
09/19/21
16:13
T

AT&T

$27.53 /

-0.05 (-0.18%)

, CMCSA

Comcast

$57.11 /

-0.19 (-0.33%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, SONY

Sony

$110.67 /

-1.59 (-1.42%)

, LGF.A

Lionsgate

$13.16 /

-0.055 (-0.42%)

, LGF.B

Lionsgate

$12.07 /

+0.02 (+0.17%)

, DIS

Disney

$183.50 /

+0.205 (+0.11%)

, VIACA

ViacomCBS

$44.41 /

-0.42 (-0.94%)

, VIAC

ViacomCBS

$39.96 /

-0.47 (-1.16%)

"Box Office Battle" is…

ShowHide Related Items >><<
VIACA ViacomCBS
$44.41 /

-0.42 (-0.94%)

VIAC ViacomCBS
$39.96 /

-0.47 (-1.16%)

T AT&T
$27.53 /

-0.05 (-0.18%)

SONY Sony
$110.67 /

-1.59 (-1.42%)

LGF.A Lionsgate
$13.16 /

-0.055 (-0.42%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$57.11 /

-0.19 (-0.33%)

T AT&T
$27.53 /

-0.05 (-0.18%)

09/09/21 LightShed Partners
T-Mobile initiated with a Neutral at LightShed Partners
09/08/21
Fly Intel: Top five analyst initiations
09/08/21 LightShed Partners
AT&T initiated with a Buy at LightShed Partners
08/31/21 Citi
AT&T price target lowered to $32 from $34 at Citi
CMCSA Comcast
$57.11 /

-0.19 (-0.33%)

09/14/21 KeyBanc
Comcast talked down Q3 internet net additions, says KeyBanc
07/30/21 Truist
Comcast price target raised to $70 from $65 at Truist
07/30/21 Morgan Stanley
Comcast price target raised to $72 from $70 at Morgan Stanley
07/30/21 Deutsche Bank
Comcast price target raised to $68 from $65 at Deutsche Bank
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
10/07/20 Benchmark
Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
09/22/20 Benchmark
Comcast price target raised to $60 from $54 at Benchmark
SONY Sony
$110.67 /

-1.59 (-1.42%)

09/10/21 Truist
Apple will likely appeal ruling in Epic case, says Truist
07/27/21 Morgan Stanley
Sony upgraded to Overweight at Morgan Stanley on animation business growth
07/27/21 Morgan Stanley
Sony upgraded to Overweight from Equal Weight at Morgan Stanley
LGF.A Lionsgate
$13.16 /

-0.055 (-0.42%)

07/22/21 Deutsche Bank
Lionsgate downgraded to Hold from Buy at Deutsche Bank
06/04/21 Barrington
Lionsgate price target raised to $27 from $16 at Barrington
06/01/21 Cowen
Lionsgate price target raised to $23 from $20 at Cowen
05/28/21 RBC Capital
Lionsgate price target raised to $17 from $13 at RBC Capital
LGF.B Lionsgate
$12.07 /

+0.02 (+0.17%)

05/26/21 Truist
Amazon's MGM deal 'a very modest negative' for Netflix/Disney, says Truist
05/26/21 Loop Capital
Lionsgate price target raised to $21 from $16 at Loop Capital
DIS Disney
$183.50 /

+0.205 (+0.11%)

09/13/21 Stephens
Recent Apple TV+ news positive for Roku, says Stephens
09/09/21 Arete
Disney initiated with a Buy at Arete
08/30/21 JPMorgan
Movie executives see 10% of screens closing, down from 15%, says JPMorgan
VIACA ViacomCBS
$44.41 /

-0.42 (-0.94%)

01/05/21 Gabelli
ViacomCBS named a best idea for 2021 at Gabelli
VIAC ViacomCBS
$39.96 /

-0.47 (-1.16%)

08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Wells Fargo
ViacomCBS upgraded to Overweight from Equal Weight at Wells Fargo
08/06/21
Fly Intel: Top five analyst upgrades
08/06/21 Deutsche Bank
ViacomCBS upgraded on 'more reasonable' valuation at Deutsche Bank
VIACA ViacomCBS
$44.41 /

-0.42 (-0.94%)

T AT&T
$27.53 /

-0.05 (-0.18%)

SONY Sony
$110.67 /

-1.59 (-1.42%)

LGF.A Lionsgate
$13.16 /

-0.055 (-0.42%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

CMCSA Comcast
$57.11 /

-0.19 (-0.33%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VIACA ViacomCBS
$44.41 /

-0.42 (-0.94%)

T AT&T
$27.53 /

-0.05 (-0.18%)

SONY Sony
$110.67 /

-1.59 (-1.42%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$57.11 /

-0.19 (-0.33%)

T AT&T
$27.53 /

-0.05 (-0.18%)

SONY Sony
$110.67 /

-1.59 (-1.42%)

LGF.A Lionsgate
$13.16 /

-0.055 (-0.42%)

CMCSA Comcast
$57.11 /

-0.19 (-0.33%)

VIAC ViacomCBS
$39.96 /

-0.47 (-1.16%)

T AT&T
$27.53 /

-0.05 (-0.18%)

SONY Sony
$110.67 /

-1.59 (-1.42%)

DIS Disney
$183.50 /

+0.205 (+0.11%)

CMCSA Comcast
$57.11 /

-0.19 (-0.33%)

Conference/Events
Morgan Stanley economist to hold an analyst/industry conference call » 16:08
09/19/21
09/19
16:08
09/19/21
16:08

Chief Economic Advisor…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Periodicals
Push to expand Tesla driver assistance rankles a top safety authority, WSJ says » 15:58
09/19/21
09/19
15:58
09/19/21
15:58
TSLA

Tesla

$759.92 /

+2.995 (+0.40%)

Tesla is readying a major…

Tesla is readying a major upgrade of its driver-assistance software, but the country's top crash investigator says the move may be premature, The Wall Street Journal's Rebecca Elliott reports. Chief Executive Elon Musk last week said drivers would soon be able to request an enhanced version of what Tesla calls its "Full Self-Driving Capability." The upgrade is expected to add a feature intended to help vehicles navigate cities, expanding the suite of driver-assistance tools that had been designed mainly for highways. Jennifer Homendy, the new head of the National Transportation Safety Board, said Tesla shouldn't roll out the city-driving tool before addressing what the agency views as safety deficiencies in the company's technology, the author notes. "Basic safety issues have to be addressed before they're then expanding it to other city streets and other areas," she said in an interview. Homendy also expressed concern about how Tesla software is tested on public roadways, the publication adds. Reference Link

ShowHide Related Items >><<
TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

09/17/21 Morgan Stanley
520 mile EPA range 'an important milestone' for Lucid, says Morgan Stanley
09/17/21 Wedbush
Tesla EV demand story just starting to play out, says Wedbush
09/15/21 BofA
BofA calls Lucid the 'Tesla/Ferrari of new EV automakers,' starts at Buy
09/10/21 Craig-Hallum
VIA Optronics price target lowered to $14 from $18 at Craig-Hallum
TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

TSLA Tesla
$759.92 /

+2.995 (+0.40%)

Periodicals
India antitrust probe finds Google abused Android dominance, Reuters reports » 15:53
09/19/21
09/19
15:53
09/19/21
15:53
GOOG

Alphabet

$2,828.63 /

-59.36 (-2.06%)

, GOOGL

Alphabet Class A

$2,816.43 /

-54.36 (-1.89%)

India's antitrust…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GOOG Alphabet
$2,828.63 /

-59.36 (-2.06%)

GOOG Alphabet
$2,828.63 /

-59.36 (-2.06%)

09/17/21 Jefferies
Alphabet price target raised to $3,325 from $3,150 at Jefferies
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Alphabet Class A initiated with a Buy at Goldman Sachs
09/09/21 JPMorgan
Netflix, Uber added as top U.S. Internet picks at JPMorgan
GOOGL Alphabet Class A
$2,816.43 /

-54.36 (-1.89%)

GOOG Alphabet
$2,828.63 /

-59.36 (-2.06%)

GOOGL Alphabet Class A
$2,816.43 /

-54.36 (-1.89%)

GOOG Alphabet
$2,828.63 /

-59.36 (-2.06%)

GOOGL Alphabet Class A
$2,816.43 /

-54.36 (-1.89%)

GOOG Alphabet
$2,828.63 /

-59.36 (-2.06%)

GOOGL Alphabet Class A
$2,816.43 /

-54.36 (-1.89%)

Hot Stocks
Facebook says WSJ stories 'contained deliberate mischaracterizations ' » 15:46
09/19/21
09/19
15:46
09/19/21
15:46
FB

Facebook

$364.61 /

-8.48 (-2.27%)

Nick Clegg,…

Nick Clegg, Facebook's vice president of global affairs, writing in a blog post, said that, "A lot has been said about Facebook this week. A series of articles published by the Wall Street Journal has focused on some of the most difficult issues we grapple with as a company - from content moderation and vaccine misinformation, to algorithmic distribution and the well-being of teens. These are serious and complex issues, and it is absolutely legitimate for us to be held to account for how we deal with them. But these stories have contained deliberate mischaracterizations of what we are trying to do, and conferred egregiously false motives to Facebook's leadership and employees. At the heart of this series is an allegation that is just plain false: that Facebook conducts research and then systematically and willfully ignores it if the findings are inconvenient for the company. This impugns the motives and hard work of thousands of researchers, policy experts and engineers at Facebook who strive to improve the quality of our products, and to understand their wider (positive and negative) impact. It's a claim which could only be made by cherry-picking selective quotes from individual pieces of leaked material in a way that presents complex and nuanced issues as if there is only ever one right answer. With any research, there will be ideas for improvement that are effective to pursue and ideas where the tradeoffs against other important considerations are worse than the proposed fix. The fact that not every idea that a researcher raises is acted upon doesn't mean Facebook teams are not continually considering a range of different improvements. At the same time, none of these issues can be solved by technology companies alone, which is why we work in close partnership with researchers, regulators, policymakers and others. But none of that collaborative work is helped by taking a deliberately lop-sided view of the wider facts."Reference Link

ShowHide Related Items >><<
FB Facebook
$364.61 /

-8.48 (-2.27%)

FB Facebook
$364.61 /

-8.48 (-2.27%)

09/17/21 Jefferies
Facebook price target raised to $440 from $425 at Jefferies
09/13/21 Goldman Sachs
Facebook initiated with a Buy at Goldman Sachs
09/09/21 JPMorgan
Netflix, Uber added as top U.S. Internet picks at JPMorgan
09/09/21 HSBC
Facebook price target raised to $300 from $275 at HSBC
FB Facebook
$364.61 /

-8.48 (-2.27%)

FB Facebook
$364.61 /

-8.48 (-2.27%)

FB Facebook
$364.61 /

-8.48 (-2.27%)

FB Facebook
$364.61 /

-8.48 (-2.27%)

Periodicals
U.S. trade official called India's MasterCard ban 'draconian,' Reuters reports » 15:39
09/19/21
09/19
15:39
09/19/21
15:39
MA

MasterCard

$343.00 /

-3.325 (-0.96%)

, AXP

American Express

$163.98 /

+1.345 (+0.83%)

A senior U.S. trade…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

MA MasterCard
$343.00 /

-3.325 (-0.96%)

09/03/21 Deutsche Bank
Deutsche says many concerns over Visa and MasterCard are minor
08/17/21 JPMorgan
MasterCard price target raised to $430 from $427 at JPMorgan
08/12/21 Daiwa
MasterCard downgraded to Neutral from Outperform at Daiwa
08/02/21 Mizuho
MasterCard price target raised to $450 from $435 at Mizuho
AXP American Express
$163.98 /

+1.345 (+0.83%)

09/16/21
Fly Intel: Top five analyst upgrades
09/16/21 BofA
American Express upgraded to Neutral at BofA on accelerating QTD billings
09/16/21 BofA
American Express upgraded to Neutral from Underperform at BofA
08/30/21
Fly Intel: Top five analyst initiations
MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

MA MasterCard
$343.00 /

-3.325 (-0.96%)

AXP American Express
$163.98 /

+1.345 (+0.83%)

Periodicals
Fauci says key data on J&J, Moderna COVID boosters weeks away, Reuters reports » 15:31
09/19/21
09/19
15:31
09/19/21
15:31
JNJ

Johnson & Johnson

$164.77 /

-0.41 (-0.25%)

, MRNA

Moderna

$429.30 /

-11.54 (-2.62%)

President Joe…

President Joe Biden's chief medical adviser Anthony Fauci said on Sunday that data needed to determine the advisability of booster shots of the Moderna Inc (MRNA) and Johnson & Johnson (JNJ) COVID-19 vaccines is just weeks away, Reuters' Chris Prentice reports. Health officials signaled they expected boosters would ultimately be recommended for a broad swath of the population, but urged Americans not to seek booster doses until they have FDA approval. "We recommend that people wait until you get to the point where you fall into the category where it's recommended," Fauci said. Reference Link

ShowHide Related Items >><<
MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades J&J to Equal Weight amid limited mid-term newsflow
MRNA Moderna
$429.30 /

-11.54 (-2.62%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
08/12/21 Wells Fargo
Wells says Moderna vaccine looks more effective than Pfizer's against Delta
08/06/21
Fly Intel: Top five analyst downgrades
MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

MRNA Moderna
$429.30 /

-11.54 (-2.62%)

JNJ Johnson & Johnson
$164.77 /

-0.41 (-0.25%)

Hot Stocks
Seagen, Genmab present interim results from innovaTV 205 study » 15:11
09/19/21
09/19
15:11
09/19/21
15:11
SGEN

Seagen

$156.26 /

+2.57 (+1.67%)

, GMAB

Genmab

$43.10 /

+0.845 (+2.00%)

Seagen (SGEN) and Genmab…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SGEN Seagen
$156.26 /

+2.57 (+1.67%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

SGEN Seagen
$156.26 /

+2.57 (+1.67%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
GMAB Genmab
$43.10 /

+0.845 (+2.00%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
SGEN Seagen
$156.26 /

+2.57 (+1.67%)

GMAB Genmab
$43.10 /

+0.845 (+2.00%)

Hot Stocks
Verastem highlights data from investigator-sponsored Phase 1/2 FRAME study » 15:08
09/19/21
09/19
15:08
09/19/21
15:08
VSTM

Verastem

$2.76 /

+0.06 (+2.23%)

Verastem Oncology…

Verastem Oncology announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study. The FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, is investigating VS-6766, Verastem's RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low grade serous ovarian cancer. Among the evaluable patients with LGSOC, the overall response rate was 46%. Among the patients with KRAS mutant LGSOC, the ORR was 64%. Among the patients with KRAS wild type LGSOC, the ORR was 44%. Of the evaluable patients, 10 received previous MEK inhibitor therapy. The mPFS across all patients was 23.0 months. As of the April 2021 data cutoff date, 13 of 24 patients remained on study. In the FRAME study, the most common Grade 3/4 treatment-related adverse events were creatine kinase elevation, rash, diarrhea, mouth ulcer/mucositis/glossitis and hyperbilirubinemia, with only one discontinuation due to AEs as of the data cutoff. "These updated data suggest that the novel, intermittent dosing schedule used in the FRAME study continues to show encouraging clinical activity in patients with recurrent LGSOC, including in patients previously treated with a MEK inhibitor," the company said. Expansion cohorts are also ongoing in pancreatic cancer, KRAS/BRAF mutant endometrioid cancer and KRAS-G12V NSCLC.

ShowHide Related Items >><<
VSTM Verastem
$2.76 /

+0.06 (+2.23%)

VSTM Verastem
$2.76 /

+0.06 (+2.23%)

07/01/21 Alliance Global Partners
Verastem initiated with a Buy at Alliance Global Partners
05/24/21 BTIG
Verastem upgraded to Buy from Neutral at BTIG
05/24/21 BTIG
Verastem upgraded to Buy from Neutral at BTIG
VSTM Verastem
$2.76 /

+0.06 (+2.23%)

VSTM Verastem
$2.76 /

+0.06 (+2.23%)

Hot Stocks
Mirati Therapeutics announces results from cohort of Phase 1/2 KRYSTAL-1 study » 15:04
09/19/21
09/19
15:04
09/19/21
15:04
MRTX

Mirati Therapeutics

$173.76 /

+4.65 (+2.75%)

Mirati Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$173.76 /

+4.65 (+2.75%)

MRTX Mirati Therapeutics
$173.76 /

+4.65 (+2.75%)

09/07/21 JPMorgan
Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan
08/26/21 Morgan Stanley
Mirati Therapeutics initiated with an Equal Weight at Morgan Stanley
08/26/21 Morgan Stanley
Mirati Therapeutics initiated with an Equal Weight at Morgan Stanley
06/04/21 Citi
Mirati Therapeutics upgraded to Buy from Neutral at Citi
MRTX Mirati Therapeutics
$173.76 /

+4.65 (+2.75%)

  • 28
    Oct
MRTX Mirati Therapeutics
$173.76 /

+4.65 (+2.75%)

Hot Stocks
Merck presents first results from Phase 3 KEYNOTE-716 trial » 14:57
09/19/21
09/19
14:57
09/19/21
14:57
MRK

Merck

$71.70 /

-0.25 (-0.35%)

Merck announced the first…

Merck announced the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with KEYTRUDA, Merck's anti-PD-1 therapy, showed a statistically significant and clinically meaningful improvement in recurrence-free survival, the trial's primary endpoint, compared to placebo in patients with resected high-risk stage II melanoma; KEYTRUDA is the first anti-PD-1 therapy to demonstrate this. At the first interim analysis, KEYTRUDA reduced the risk of disease recurrence or death by 35% compared to placebo. Median RFS had not been reached for either group at the time of this analysis. After 14.4 months follow-up, 11.1% of patients on KEYTRUDA had recurrence or died compared with 16.8% of patients on placebo, with fewer distant recurrences with KEYTRUDA versus placebo. The safety profile of KEYTRUDA was consistent with previously reported studies in patients with solid tumors. Treatment-related adverse events occurred in 79.9.% of patients who received KEYTRUDA versus 60.9% of patients who received placebo, while Grade 3 or 4 TRAEs were observed in 16.1% versus 4.3% of patients, respectively.

ShowHide Related Items >><<
MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

Hot Stocks
Merck presents full results from pivotal Phase 3 KEYNOTE-826 trial » 14:54
09/19/21
09/19
14:54
09/19/21
14:54
MRK

Merck

$71.70 /

-0.25 (-0.35%)

Merck announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley downgrades Merck to Equal Weight, awaits strategic action
09/07/21 Morgan Stanley
Merck downgraded to Equal Weight from Overweight at Morgan Stanley
MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

MRK Merck
$71.70 /

-0.25 (-0.35%)

Hot Stocks
Spectrum presents results from Cohort 4 of ZENITH20 clinical trial » 14:46
09/19/21
09/19
14:46
09/19/21
14:46
SPPI

Spectrum

$2.44 /

+0.1 (+4.27%)

Spectrum Pharmaceuticals…

Spectrum Pharmaceuticals announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial. This data is from 48 first-line patients with non-small cell lung cancer with HER2 exon 20 insertion mutations who received 16mg of oral poziotinib once daily. These results showed a confirmed objective response rate of 44%, as evaluated centrally by an independent image review committee using RECIST 1.1 criteria. The data was presented as a late breaker at the European Society for Medical Oncology Congress 2021 taking place in Paris on September 16-20, 2021. Cohort 4 of the ZENITH20 clinical trial is enrolling treatment-naive NSCLC patients with HER2 exon 20 insertion mutations. This cohort is investigating the efficacy of poziotinib with a QD and BID - ongoing - dosing strategy. Poziotinib 16mg was administered orally once daily for the first 48 patients allowing dose reductions/interruptions for toxicity. The primary endpoint was ORR evaluated centrally by an independent image review committee using RECIST 1.1 criteria. Secondary endpoints included disease control rate, duration of response, progression-free survival and safety. The primary endpoint of ORR was 44% in the 48 treated patients including one complete response. 88% of patients showed tumor reduction with a DCR of 75%. Median DoR was 5.4 months. Median PFS was 5.6 months. 88% of patients had dose interruptions and 77% had reductions from the 16mg QD starting dose, while 13% had adverse event related discontinuations. Only 1 patient experienced Grade greater than or equal to 3 pneumonitis. Poziotinib demonstrated clinically meaningful anti-tumor activity in newly diagnosed NSCLC patients with HER2 exon 20 mutations with 16mg QD dosing. The safety profile was manageable and similar to previously seen in previous studies and other second-generation tyrosine kinase inhibitors. The 8mg BID portion of Cohort 4 is continuing to actively recruit.

ShowHide Related Items >><<
SPPI Spectrum
$2.44 /

+0.1 (+4.27%)

SPPI Spectrum
$2.44 /

+0.1 (+4.27%)

08/18/21 B. Riley
Spectrum price target lowered to $6 from $8 at B. Riley
06/01/21 H.C. Wainwright
H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility
10/26/20 H.C. Wainwright
Spectrum won't need to refile as CRL not given, says H.C. Wainwright
SPPI Spectrum
$2.44 /

+0.1 (+4.27%)

SPPI Spectrum
$2.44 /

+0.1 (+4.27%)

Hot Stocks
Exelixis announces detailed Phase 1b results from cohort 6 of COSMIC-021 trial » 14:42
09/19/21
09/19
14:42
09/19/21
14:42
EXEL

Exelixis

$20.74 /

+0.205 (+1.00%)

Exelixis announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

Hot Stocks
AstraZeneca presents data from Phase II DESTINY-Lung01 trial of ENHERTU » 14:39
09/19/21
09/19
14:39
09/19/21
14:39
AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

Detailed primary results…

Detailed primary results from the Phase II DESTINY-Lung01 trial of ENHERTU, the AstraZeneca and Daiichi Sankyo HER2-directed antibody drug conjugate, showed a robust and durable tumor response in previously treated patients with HER2-mutant unresectable and/or metastatic non-squamous non-small cell lung cancer. Results presented during a late-breaking Proffered Paper session at the European Society for Medical Oncology Congress 2021 and simultaneously published in The New England Journal of Medicine confirm ENHERTU as the first HER2-directed therapy to show a strong tumor response in this patient population. Primary results from the HER2m cohort of DESTINY-Lung01 in previously treated HER2m NSCLC demonstrated a confirmed objective response rate of 54.9% in patients treated with ENHERTU as assessed by independent central review. One complete response and 49 partial responses were observed. A confirmed disease control rate of 92.3% was seen with a reduction in tumor size observed in most patients. After a median follow-up of 13.1 months, the median duration of response for ENHERTU was 9.3 months. The median progression-free survival was 8.2 months and the median overall survival was 17.8 months. Responses were observed across HER2m subtypes, as well as in patients with no detectable HER2 expression or HER2 gene amplification. Efficacy was observed in subgroups including prior treatment with platinum-based therapy, or platinum-based and anti-PD-(L)1 therapy, as well as asymptomatic brain metastases at baseline.

ShowHide Related Items >><<
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

Hot Stocks
Novartis announces results of final OS analysis of Phase III MONALEESA-2 study » 09:41
09/19/21
09/19
09:41
09/19/21
09:41
NVS

Novartis

$83.49 /

-0.88 (-1.04%)

Novartis has announced…

Novartis has announced results of the final overall survival analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. Kisqali in combination with letrozole met its key secondary endpoint of OS, demonstrating a statistically significant and clinically meaningful improvement in survival. The analysis found that after a median follow-up of over six and a half years, the longest for any CDK4/6 inhibitor trial to date, the improvement in the median OS was over one year. MONALEESA-2 showed that after five years, patients treated with Kisqali in combination with letrozole had more than a 50% chance of survival. In MONALEESA-2, a 12-month delay in time to chemotherapy was observed with Kisqali compared to those taking letrozole alone. With this longer follow-up, no new safety signals were observed; adverse events were consistent with previously reported Phase III trial results for Kisqali. In MONALEESA-2, the primary endpoint progression-free survival was met at the initial analysis. These new OS results mark the third statistically significant and clinically meaningful survival benefit achieved by Kisqali in the MONALEESA program. Novartis will submit the data to global health authorities to support label updates.

ShowHide Related Items >><<
NVS Novartis
$83.49 /

-0.88 (-1.04%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
07/27/21 Jefferies
Point Biopharma initiated with a Hold at Jefferies
NVS Novartis
$83.49 /

-0.88 (-1.04%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

NVS Novartis
$83.49 /

-0.88 (-1.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.